Access Pharmaceuticals Inc., an emerging biopharmaceutical company, is focused on developing novel nanopolymer delivery technologies and products for cancer and dermatology. Currently, the company has one approved product, one product in phase 3 clinical development, four products in phase 2, and six products in preclinical development.
Although Access’ primary focus is on oncology and supportive care of cancer patients, the company has acquired product candidates in the dermatology field as well as additional oncology assets. The business development team is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for the company’s oncology and dermatology products, as well as nanopolymer technologies.
In most recent news, Access announced that it has received issue notifications from the United States Patent and Trademark Office that two US patents relating to MuGard TM , the company’s approved oral rinse product for the management of mucositis, will issue this month. MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Access also told investors that MuGard™ was launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm. Under a license from Access Pharmaceuticals Inc., SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. The pharmaceutical company plans to launch MuGard in the rest of Europe within the next 12 to 18 months.
Commenting on the news, Phillip Wise, Vice President of Business Development at Access, stated, “SpePharm and Access are pleased with the commercial launch of MuGard in Europe, and while it is still in the early days, initial feedback has been positive. SpePharm is working hard to secure reimbursement from the individual governmental regulators, which we believe will greatly enhance initial product adoption and ongoing marketing efforts to reach and penetrate the target population of patients requiring this important treatment option.”
Let us hear your thoughts: Access Pharmaceuticals Inc. Message Board
